Novo-Nordisk A/S (NVO) is a publicly traded Healthcare sector company. As of May 20, 2026, NVO trades at $44.93 with a market cap of $196.24B and a P/E ratio of 0.00. NVO moved +1.77% today. Year to date, NVO is -15.48%; over the trailing twelve months it is -33.93%. Its 52-week range spans $35.12 to $125.62. Analyst consensus is neutral with an average price target of $43.00. Rallies surfaces NVO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Novo Nordisk Plans International Wegovy Launch After 2M US Prescriptions: Novo Nordisk expects to begin international launches of its oral Wegovy obesity pill later this year pending regulatory approvals, aiming to build on over two million U.S. prescriptions that propelled first-quarter sales above forecasts. AstraZeneca’s FDA approval of Baxfendy for hypertension adds new competition in the cardiovascular and metabolic market.
| Metric | Value |
|---|---|
| Price | $44.93 |
| Market Cap | $196.24B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 1.22% |
| 52-Week High | $125.62 |
| 52-Week Low | $35.12 |
| Volume | 9.29M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
8 analysts cover NVO: 0 strong buy, 1 buy, 7 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $43.00.